Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 136

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1A
Chunk 136
---
 of safety
and efficacy, there can be no assurance that these results will be confirmed in subsequent clinical trials or studies or provide a sufficient
basis for regulatory approval, if required. In addition, side effects observed in clinical trials or studies, or other side effects that
appear in later clinical trials or studies, may adversely affect our or our distributors’ ability to market and commercialize our
products.

Our
operations rely on third parties to produce our raw materials to produce our products.

We
rely on independent third parties to produce the raw materials (e.g. collagen, elastin, and heparin) that we use to produce our Spryng®
products. As such, we are dependent upon their services and will not be in a position to control their operations as we might if we directly
produced these raw materials. While we believe the raw materials used to manufacture Spryng® products are readily available and can
be obtained from multiple reliable sources on a timely basis, circumstances outside our control may impair our ability to have an adequate
supply of raw materials to produce our Spryng® products.

16

If
we experience the rapid commercial growth of Spryng®, we may not be able to manage such growth effectively.

We
contemplate rapid growth for our business as we bring our Spryng® product to new customers and anticipate that this will
place significant demands on our management and our operational and financial resources. Our organizational structure will become more
complex as we add additional personnel, and we would likely require more financial and staff resources to support and continue our growth.
If we are unable to manage our growth effectively, our business, financial condition, and results of operations may be materially harmed.

Our
Distribution Agreements with Vedco and Clipper Distributing are important to our business and if we were to lose our Distribution Agreements
it would adversely affect our revenues and profitability. 

In
December 2024, we entered into distribution partnerships with Vedco and Clipper Distributing. Both distribution partnerships are important
to our business. We generated 43% of our total revenues from Spryng® products sold under the distribution partnerships
in the fiscal year ended March 31, 2025.

We
entered into a Distribution Agreement with MWI in June 2022. We generated 38% of our total revenues from Spryng® products
sold under the Distribution Agreement in the fiscal year ended March 31, 2025. In March 2025, we mutually terminated